Coya Therapeutics, Inc. financial data

Symbol
COYA on Nasdaq
Location
12645 Memorial Dr., Suite F1 #305, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 907 % -8.58%
Debt-to-equity 15.3 % +10%
Return On Equity -57.4 % -81.3%
Return On Assets -49.7 % -79.1%
Operating Margin -517 % -335%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.9M shares +25.2%
Common Stock, Shares, Outstanding 16.7M shares +10%
Entity Public Float 85.2M USD +134%
Common Stock, Value, Issued 1.68K USD +9.98%
Weighted Average Number of Shares Outstanding, Basic 16.7M shares +9.93%
Weighted Average Number of Shares Outstanding, Diluted 16.7M shares +9.93%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.99M USD -58.3%
General and Administrative Expense 10.3M USD +13.1%
Operating Income (Loss) -20.6M USD -81.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.09M USD -111%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -18.4M USD -72.3%
Earnings Per Share, Basic -1 USD/shares -68.2%
Earnings Per Share, Diluted -1 USD/shares -68.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.1M USD -9.43%
Assets, Current 32M USD -9.81%
Property, Plant and Equipment, Net 18.1K USD -60.2%
Assets 32M USD -9.87%
Accounts Payable, Current 1.11M USD +230%
Accrued Liabilities, Current 1.64M USD +16.3%
Liabilities, Current 3.67M USD +58.1%
Liabilities 4.76M USD +34.4%
Retained Earnings (Accumulated Deficit) -56.3M USD -48.7%
Stockholders' Equity Attributable to Parent 27.3M USD -14.8%
Liabilities and Equity 32M USD -9.87%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.83M USD -232%
Net Cash Provided by (Used in) Financing Activities 19.1K USD -98.5%
Net Cash Provided by (Used in) Investing Activities -25K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 16.7M shares +10%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 8.13M USD +44.5%
Depreciation 27.4K USD 0%
Property, Plant and Equipment, Gross 137K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 1.35M USD +208%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 83.5M USD +19.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 3.98M USD +88.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%